American Cryostem | americancryostem.com
American CryoStem provides clinical grade, adipose tissue derived adult stem cell processing and cryo-preservation solutions.
AMERICAN CRYOSTEM CEO
Chairman & CEO
How would you rate John Arnone as a CEO?
What is American Cryostem's revenue?
How many people work at American Cryostem?
Followers on Owler
Add a company or two. We won't bite!
Add a new competitor:
Thanks for your contribution!
Recalculating The Competitive Graph now...
American Cryostem was founded in 06/2008 and its headquarters is located in Eatontown, New Jersey, USA. American Cryostem has $2.1M in revenue and 10 employees.
Coming soon with Owler Pro!
If you'd like to learn more, please contact us at email@example.com
Coming soon with Owler Pro!
If you'd like to learn more, please contact us at firstname.lastname@example.org
|American Cryostem: American Cryostem Corp : American Cryostem Corporation 2017 Year End Update(4-traders.com) EATONTOWN, NJ / ACCESSWIRE / January 16, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released Summary corporate and financial highlight information regarding...http://www.4-traders.com/AMERICAN-CRYOSTEM-CORP-10323125/news/American-Cryostem-Corp-American-Cryostem-Corporation-2017-Year-End-Update-25812289/?utm_medium=RSS&utm_content=201801164-traders|
|Press coverage of American Cryostem more than tripled over the last week, reaching four mentionsAmerican Cryostem made the news four times in the past week, including articles in PharmaTech, Pharmaceutical Processing and The Pharma Letter. This is about four times more than the usual press coverage the company receives.|
|American Cryostem: FDA Issues Warning Letter to American CryoStemFDA sent a warning letter, dated Jan. 3, 2018, to American CryoStem and its Chairman/CEO, John S. Arnone, for marketing an adipose-derived stem cell product without agency approval and for significant deviations from current good manufacturing practice (CGMP) requirements, including some that raPharmaTech|
|American Cryostem: BRIEF-FDA Warns American Cryostem Of Deviations Related To Co's Stem Cell Product* FDA WARNS AMERICAN CRYOSTEM CORPORATION OF SIGNIFICANT DEVIATIONS RELATED TO ITS UNAPPROVED STEM CELL PRODUCT, ATCELLReuters|
|American Cryostem: American CryoStem Corporation (OTCMKTS:CRYO) Files An 8-K Changes in Registrant's Certifying AccountantOn December 6, 2017, the Registrant was notified by its independent auditor, Leigh J. Kremer, Certified Public Accountant (“Kremer”) that Kremer was discontinuing providing its public company accounting practice to CRYO and was therefore resigning as CRYO’s independent auditor. A copy of the resignation letter is attached as Exhibit 99.1 to this Current Report on Form 8-Kmarketexclusive|
|American Cryostem: American CryoStem Corp CRYO Financial and Strategic SWOT Analysis Review Report Updated 13112017 Prices from USD $300SummaryAmerican CryoStem Corp American CryoStem formerly Advanced Wound TechnologiesMidAtlantic LLC is a developer manufacturer and marketer of lifeenhancing stem cell technologies. The company offers tissue collection and transportation adipose derived st...BioPortfolio|
|Press Release: American Cryostem : American CryoStem Secures a Major Contract in Mainland ChinaEATONTOWN, NJ / ACCESSWIRE / September 25, 2017 / American CryoStem Corporation (PINK SHEETS: CRYO) today announced a major transaction in mainland China with Health Innovative Technology of Hong Kong (HIT). After more than two years as CRYO's licensee in Hong Kong, HIT has licensed the patent rights to distribute the Company's ATGRAFT and CELLECT platform in mainland China.To facilitate the expansion, CRYO has extended the licensing and distribution agreement with HIT to establish two additional entities; Health Innovative Technology Shenzhen (HITSZ) and Baoxin Asia Pacific Biotechnology Co, LTD (Baoxin), which will develop, own and operate multiple laboratory/treatment/training facilities in China.CRYO has received an upfront fee of $300,000 USD and a 5-year minimum annual guarantee of $500,000 USD per year. Additionally, as part of the transaction CRYO will obtain a minority equity stake in Baoxin, (China) and up to a 20% equity ownership interest in the Regenerative Medicine center in Hong Kong (HK).According to South China Morning Post industry analysts estimate that China's cosmetic surgery industry will double by 2019 making it the third largest market in the world behind the U.S. and Brazil. Additionally, CRYO's ATGRAFT fat tissue platform is a natural alternative to one of the most popular procedures in China, hyaluronic acid (HA) dermal filler injection which enhances facial contours, reduce wrinkles, hydrate and firm the skin.John Arnone, CEO stated, "For the past few years we have focused the expansion of our products and services into international markets. Many of these markets, including Hong Kong, have recently approved stem cell-based therapies. The HK laboratory/treatment center will take full advantage of CRYO's Regenerative Medicine Platform, (ATGRAFT, ATCELL, and CELLECT) and synergistic products including the Company's ACSelerate Max cell culture mediums. He continued, "Our long-term relationship with Health Innovative Technology of Hong Kong has provided us with a reliable partner to expand the business within China."Anthony Dudzinski, COO of CRYO added: "China is one of the world's largest markets for our technology and Regenerative Medicine platform and we believe this transaction will have a long-term positive impact on our revenues and significantly enhance the value of the Company for our shareholders."Matthew Fan, CEO of Health Innovative Technology commented, "After years of working with American CryoStem and their platform at our initial laboratory facilities in Hong Kong and Shenzhen, we are ready to expand our China operations. CRYO's tissue collection, processing and storage platform for adipose tissue has been very well received in our markets and we believe we can be the dominant player in this field. Our short-term goals are to set up two more GMP grade adipose tissue processing and storage facilitates in Beijing and Shanghai to cover the need of the whole China region, and a proper education facility in China to promote the use of ATGRAFT as a better more natural filler, over the artificial fillers."About American CryoStem Corporation:American CryoStem Corporation (PINK SHEETS: CRYO) was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, Schenzen, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose-derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology that supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physician's networks and research organizations who purchase tissue collection, processing and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our 13 patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.About Health Innovative Technology:Health Innovative Technology Corporation Limited (HIT) is a healthcare platform with diverse investment interests spanning across pharmaceutical, beauty, healthcare, and life science services. HIT is dedicated to the successful, efficient, and cost-effective execution of projects in innovative and scientifically proven biomedical technologies, including, but not limited to, stem cell storage and genome diagnostic services. HIT strives to promote the development of life science and medical technology in Greater China Region by supporting different research projects around the globe. By continually looking to import cutting-edge life science technologies, we aim at satisfying the unmet need in the highly volatile health management industry from an ethical approach.For further detailed Corporate or Regenerative Medicine information please visit: www.americancryostem.com, request by email at email@example.com or phone 732-747-1007SOURCE: American CryoStem CorporationReleaseID: 476132MarketersMedia|
|American Cryostem: COO Tony Dudzinski Highlights American CryoStem's Path to Current and Future SuccessCOO Tony Dudzinski Highlights American CryoStem's Path to Current and Future SuccessEatontown, NJ., , Sept.PharmiWeb|
|American Cryostem: American CryoStem Corporation Announces Financial Results for Q3 Fiscal 2017EATONTOWN, NJ / ACCESSWIRE / August 22, 2017 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular t...FinanzNachrichten|
|American Cryostem: American CryoStem Corporation Release: COO Was Interviewed On /b> On Product Importance And Company Improvements Life Sciences Jobs ...BioSpace|
Screengrabs of how the American Cryostem site has evloved. (Click to expand)
Owler has collected 15 screenshots of American Cryostem's website since May 2014. The latest American Cryostem website design screenshot was captured in Dec 2017.
American CryoStem provides clinical grade, adipose tissue derived adult stem cell processing and cryo-preservation solutions. American Cryostem was founded in 06/2008. American Cryostem's headquarters is located in Eatontown, New Jersey, USA 07724. American Cryostem has 10 employees and reported 2.1M in revenue [trailing four quarters].
Visit the American Cryostem website to learn more.